

EDITORIAL

Open Access



The KT Jeang retrovirology prize 2023: Thumbi Ndung'u

Thumbi Ndung'u^{1,2,3,4*}

Thumbi Ndung'u grew up on a coffee farm in rural Kenya, where he received his primary and high school education at Gathugu Primary School and Nyeri High School. He studied Veterinary Medicine at the University of Nairobi and graduated in 1991, later joining the laboratory led by George Kinoti and Jasper Mumo at the same institute, to work on *Schistosoma haematobium* vaccine research. The project provided an opportunity for Ndung'u to travel to the laboratory of Donald Harn at the Harvard School of Public Health to train on hybridoma technology for making monoclonal antibodies. Besides the cultural shock of working overseas for the first time, this exciting six-month stint at Harvard was an eye-opener to cutting-edge biomedical research. Ndung'u subsequently returned to Nairobi where he worked to set up the infrastructure to produce monoclonal antibodies to *Schistosoma haematobium* egg antigens.

Ndung'u was elated when he was admitted with a full scholarship to pursue doctoral research at Harvard in 1995. He joined the laboratory of Max Essex, who was focusing on HIV genetic diversity and its implications for disease pathogenesis and the development of biomedical interventions against the virus. The decision to focus on HIV was driven by the emerging reality that HIV was rapidly spreading in Africa, and with no effective drugs or a vaccine at the time, it was obvious that this was

going to be an important scientific challenge for Africa and the world. HIV/AIDS scientific discoveries were also rapidly emerging at the time, such as the design of highly effective antiretroviral drugs, understanding of the dynamics of HIV-1 replication in vivo, and the identification of HIV entry co-receptors and their genetic variations in human populations [1–6]. For his doctoral thesis research, Ndung'u generated the first infectious molecular clone of HIV-1 subtype C from a primary isolate of HIV-1. He also generated the first HIV-1 subtype C based simian human immunodeficiency virus chimera able to replicate in rhesus macaque cells [7–9]. Ndung'u received the Edgar Haber Award for outstanding thesis research. He also participated in other research in the laboratory to understand HIV-1 genetic variation and to study immune responses in non-B HIV-1 subtypes for vaccine development [10–13]. His work is important because subtype C HIV-1 is the most prevalent subtype globally and is predominant in southern Africa. In contrast, subtype B is more widely studied and is prevalent in Europe and the Americas.

Upon completion of his PhD, Ndung'u briefly worked under the mentorship of David Knipe as a postdoctoral fellow at Harvard, but soon decided to take a position to help lead efforts at a newly established HIV Reference Laboratory at the Botswana Harvard Partnership (BHP), a collaboration between the Botswana government and Harvard T.H. Chan School of Public Health, located in Gaborone, Botswana. The experience in Boston had been exhilarating, challenging and unforgettable, with the birth of his two children while both he and his wife were graduate students, and doing odd jobs to make ends meet while gaining superb training and savoring wonderful cultural experiences in the vibrant academic ecosystem and rich cultural history of New England. However, he

*Correspondence:

Thumbi Ndung'u
thumbi.ndungu@ahri.org

¹Africa Health Research Institute, Durban, South Africa

²HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa

³Ragon Institute of MGH, MIT and Harvard University, Cambridge, MA, USA

⁴Division of Infection and Immunity, University College London, London, UK



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

was eager to play a direct role in research and the public health response to the now burgeoning epidemic in southern Africa.

The laboratory at BHP supported the national HIV/AIDS response and facilitated clinical trials of anti-retroviral drugs and vaccine candidates. Ndung'u was involved in basic and translational laboratory research that complemented the ongoing clinical trials [14–18], helped to establish collaborative links with the University of Botswana and other institutions in the region, and co-supervised students. Although the clinical trials of anti-retroviral drugs were highly successful in Botswana and elsewhere in Africa, setting the stage for the widespread roll-out of these drugs globally, the HIV-1 vaccine trials were unsuccessful. This led to the conclusion that development of an effective HIV-1 vaccine would require better understanding of HIV biology and protective immune responses [19]. Ndung'u then decided that his skills would be better utilized within a university setting, where he would also have an opportunity to interact with and train large numbers of students. In 2005, he moved to the University of KwaZulu-Natal in Durban, South Africa, to establish his own independent research group.

The University of KwaZulu-Natal provided a unique challenge due to the high burden of infection in the province of KwaZulu-Natal. However, there was an opportunity for ground-breaking work because of a committed and activist scientific community, superb research infrastructure, and community willingness to contribute to research. Supported by colleagues such as Hoosen (Jerry) Coovadia and Salim Abdool Karim, he developed a program of work on HIV-1 pathogenesis, anchored on acute HIV-1 infection studies and the heterogeneous clinical outcomes that characterize HIV infection. With his students, he performed research on the role of immune factors, host restriction and HIV-1 replication cofactors on HIV-1 disease progression [20–25]. These studies demonstrated that regulation of expression and genetic variation of these factors could play a role in HIV-1 disease pathogenesis. Ndung'u also used cohort-based studies to explore the mechanisms of HIV-1 immune control that could be exploited for vaccine development. Several studies from his laboratory demonstrated that HIV-1 replication capacity was an important determinant of disease progression and that some “protective” human leukocyte antigen class I (HLA-I) alleles, associated with slow disease progression, mediated this effect [26–28]. These studies also defined the fitness landscape of HIV-1 subtype C Gag and Nef proteins, which are important targets for HIV vaccine design [29–31]. This work was performed in collaboration with the laboratories of Mark Brockman, Arup Chakraborty, and Bruce Walker. Other work in his laboratory showed that in individuals with protective HLA-I alleles, who naturally controlled

subtype C HIV-1 infection, viral control was associated with broad CD8+T cells that could efficiently kill the virus in ex vivo assays [32]. The Ndung'u group also showed that broad targeting of the HIV-1 Gag protein during acute HIV-1 infection is associated with relative control of the viral load set point but that these responses are not broad and rarely drive immune escape following infection, suggesting that they are defective [33–35]. Subsequent studies using HIV tetramers demonstrated that CD8+T cell immune responses are broad during acute HIV-1 infection but are defective [36]. Taken together, these studies identified vulnerable regions of the virus that may be good candidates for a vaccine designed to induce effective T cell immune responses; in the case of immune escape they may still be effective due to debilitating mutations in the virus.

Ndung'u has also contributed to research on HIV transmission and spread. The HIV-1 epidemic is composed of diverse subtypes that differ in prevalence and rates of disease progression. His group found that HIV-1 subtype C has lower replication capacity (RC) than the less prevalent subtype B [37]. Moreover, in East Africa where multiple subtypes co-exist, there is a hierarchy in virus RC such that subtypes A and C have lower RC than D, which in turn has lower RC than inter-subtype recombinants. Subtype specific differences also extend to functions of specific viral genes known to play diverse roles in disease pathogenesis [38–40]. These differences may account for the reported differences in disease progression between subtypes and the differential spread of HIV-1 subtypes globally. Interestingly, in mother to child HIV-1 transmission, the group has shown that viruses with lower RC are preferentially transmitted [41].

In addition to research on HIV immunopathogenesis to inform vaccine development, the Ndung'u group also now studies HIV reservoirs and cure strategies. Most of this work is anchored on acute HIV-1 infection and natural controller cohorts. One cohort, known as the Females Rising through Support Education and Health (FRESH) has pioneered a unique approach that combines basic science research and social economic empowerment by providing intensive HIV-1 prevention services, career and life-skills training to address issues such as high school drop-out rates, gender-based violence and economic challenges facing young women in a South African Township [42, 43]. The study is investigating factors associated with HIV-1 acquisition and the virological and immunological impact of early antiretroviral treatment with the goal of informing vaccine and cure strategies [44–48]. The group is conducting a clinical trial to test whether a combination of broadly neutralizing antibodies and a toll-like receptor agonist can lead to HIV remission off antiretroviral therapy in women who initiated treatment during the acute phase of infection.

Ndung'u is currently the director for basic and translational science at the Africa Health Research Institute (AHRI) in Durban, South Africa and the scientific director of the University of KwaZulu-Natal's HIV Pathogenesis Programme. He is a recipient of the South African Medical Research Council Gold Award and is a member of the Academy of Science of South Africa and an African Academy of Sciences Fellow. He is co-chair of the International AIDS Society Toward a Cure Board. Ndung'u is also this year's recipient of the Harvard T.H. Chan School of Public Health Leadership Award in Public Health Practice. Ndung'u has trained more than 50 students and postdoctoral fellows, many of whom are now in leading roles in academia and other industries, and is passionate about contributing to training the next generation of scientific leaders on the African continent. A role he is therefore particularly excited about is that of programme director of the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), an African-led research and capacity building consortium working in 8 African countries (South Africa, Cameroon, Uganda, Zimbabwe, Rwanda, Zambia, Kenya and Botswana).

Acknowledgements

Many outstanding individuals have undertaken research in the Ndung'u groups at the HIV Pathogenesis Programme, University of KwaZulu-Natal, and the Africa Health Research Institute. His research has been funded by many organizations including: the South African National Research Foundation, the South African Medical Research Council, the National Institutes of Health, the Howard Hughes Medical Institute, the Max Planck Society, the Wellcome Trust, the European Union, the International AIDS Vaccine Initiative, the Ragon Institute, Gilead Sciences Inc., the Science for Africa Foundation and the Bill and Melinda Gates Foundation. Ndung'u also acknowledges family members, mentors and friends who have been part of his exciting career journey.

Published online: 18 October 2023

References

- Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. *Science*. 1996;272:1955–8.
- Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al. Identification of a major co-receptor for primary isolates of HIV-1 [see comments]. *Nature*. 1996;381:661–6.
- Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, K.A. N, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. *Nature*. 1996;381:667–73.
- Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments]. *Science*. 1996;272:872–7.
- Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. *Cell*. 1996;86:367–77.
- Wei X, Ghosh SK, Taylor ME, Johnson VA, Emami EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al. Viral dynamics in human immunodeficiency virus type 1 infection. *Nature*. 1995;373:117–22.
- Ndung'u T, Lu Y, Renjifo B, Touzjian N, Kushner N, Pena-Cruz V, Novitsky VA, Lee TH, Essex M. Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate: rhesus macaque model. *J Virol*. 2001;75:11417–25.
- Ndung'u T, Renjifo B, Essex M. Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone. *J Virol*. 2001;75:4964–72.
- Ndung'u T, Renjifo B, Novitsky VA, McLane MF, Gaolekwe S, Essex M. Molecular cloning and biological characterization of full-length HIV-1 subtype C from Botswana. *Virology*. 2000;278:390–9.
- Koulińska IN, Ndung'u T, Mwakagile D, Msamanga G, Kagoma C, Fawzi W, Essex M, Renjifo B. A new human immunodeficiency virus type 1 circulating recombinant form from Tanzania. *AIDS Res Hum Retroviruses*. 2001;17:423–31.
- Montano MA, Nixon CP, Ndung'u T, Bussmann H, Novitsky VA, Dickman D, Essex M. Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function. *J Infect Dis*. 2000;181:76–81.
- Novitsky V, Montano M, McLane M, Renjifo B, Vannberg F, Foley B, Ndung'u T, Rahman M, Makhema M, Marlink R, Essex M. Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: a set of 23 full-length clones from Botswana. *J Virol*. 1999;73:4427–32.
- Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C, Ndung'u T, Klein I, Chang SY, Peter T, et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? *J Virol*. 2002;76:5435–51.
- Doualla-Bell F, Gaseitsiwe S, Ndung'u T, Modukanele M, Peter T, Novitsky V, Ndwapi N, Tendani G, Avalos A, Wester W, et al. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1 C-infected African patients. *Antivir Chem Chemother*. 2004;15:189–200.
- Ndung'u T, Gaseitsiwe S, Sepako E, Doualla-Bell F, Peter T, Kim S, Thior I, Novitsky VA, Essex M. Major histocompatibility complex class II (HLA-DRB and -DQB) allele frequencies in Botswana: association with human immunodeficiency virus type 1 infection. *Clin Diagn Lab Immunol*. 2005;12:1020–8.
- Ndung'u T, Sepako E, McLane MF, Chand F, Bedi K, Gaseitsiwe S, Doualla-Bell F, Peter T, Thior I, Moyo SM et al. HIV-1 subtype C in vitro growth and coreceptor utilization. *Virology* 2006.
- Novitsky V, Gilbert P, Peter T, McLane MF, Gaolekwe S, Rybak N, Thior I, Ndung'u T, Marlink R, Lee TH, Essex M. Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. *J Virol*. 2003;77:882–90.
- Shapiro RL, Ndung'u T, Lockman S, Smeaton LM, Thior I, Wester C, Stevens L, Sebetso G, Gaseitsiwe S, Peter T, Essex M. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. *J Infect Dis*. 2005;192:713–9.
- Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, Hoxie JA, Hunter E, Korber B, Landay A, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. *Science*. 2004;303:316.
- Madlala P, Singh R, An P, Werner L, Mlisana K, Abdool Karim SS, Winkler CA, Ndung'u T: association of polymorphisms in the Regulatory Region of the Cyclophilin A gene (PPIA) with gene expression and HIV/AIDS disease progression. *J Acquir Immune Defic Syndr*. 2016;72:465–73.
- Naicker DD, Werner L, Kormuth E, Passmore JA, Mlisana K, Karim SA, Ndung'u T: Interleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis. *J Infect Dis*. 2009;200:448–52.
- Reddy K, Ooms M, Letko M, Garrett N, Simon V, Ndung'u T. Functional characterization of vif proteins from HIV-1 infected patients with different APOBEC3G haplotypes. *AIDS*. 2016;30:1723–9.
- Reddy K, Winkler CA, Werner L, Mlisana K, Abdool Karim SS, Ndung'u T. APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. *AIDS*. 2010;24:195–204.
- Sewram S, Singh R, Kormuth E, Werner L, Mlisana K, Karim SS, Ndung'u T, Team CAIS. Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. *J Infect Dis*. 2009;199:1657–63.
- Singh R, Patel V, Mureithi MW, Naranbhai V, Ramsuran D, Tulsi S, Hiramani K, Werner L, Mlisana K, Altfeld M, et al. TRIM5alpha and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment. *J Virol*. 2014;88:4291–303.
- Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, Brumme CJ, Wang B, Losina E, Miura T, Chonco F, et al. Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. *J Virol*. 2010;84:10820–31.

27. Wright JK, Naidoo VL, Brumme ZL, Prince JL, Claiborne DT, Goulder PJ, Brockman MA, Hunter E. Ndung'u T: impact of HLA-B*81-associated mutations in HIV-1 gag on viral replication capacity. *J Virol*. 2012;86:3193–9.
28. Wright JK, Novitsky V, Brockman MA, Brumme ZL, Brumme CJ, Carlson JM, Heckerman D, Wang B, Losina E, Leshwedi M, et al. Influence of gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. *J Virol*. 2011;85:3996–4006.
29. Barton JP, Rajkumar E, Mann JK, Murakowski DK, Toyoda M, Mahiti M, Mwimanzani P, Ueno T, Chakraborty AK. Ndung'u T: modelling and in vitro testing of the HIV-1 Nef fitness landscape. *Virus Evol*. 2019;5:vez029.
30. Ferguson AL, Mann JK, Omarjee S, Ndung'u T, Walker BD, Chakraborty AK. Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. *Immunity*. 2013;38:606–17.
31. Mann JK, Barton JP, Ferguson AL, Omarjee S, Walker BD, Chakraborty A, Ndung'u T. The fitness landscape of HIV-1 gag: advanced modeling approaches and validation of model predictions by in vitro testing. *PLoS Comput Biol*. 2014;10:e1003776.
32. Koofhethile CK, Ndhlovu ZM, Thobakgale-Tshabalala C, Prado JG, Ismail N, Mncube Z, Mkhize L, van der Stok M, Yende N, Walker BD, et al. CD8 + T cell breadth and Ex vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without protective HLA class I alleles. *J Virol*. 2016;90:6818–31.
33. Gounder K, Padayachi N, Mann JK, Radebe M, Mokgoro M, van der Stok M, Mkhize L, Mncube Z, Jaggernath M, Reddy T, et al. High frequency of transmitted HIV-1 gag HLA class I-driven immune escape variants but minimal immune selection over the first year of clade C infection. *PLoS ONE*. 2015;10:e0119886.
34. Radebe M, Gounder K, Mokgoro M, Ndhlovu ZM, Mncube Z, Mkhize L, van der Stok M, Jaggernath M, Walker BD. Ndung'u T: broad and persistent gag-specific CD8 + T-cell responses are associated with viral control but rarely drive viral escape during primary HIV-1 infection. *AIDS*. 2015;29:23–33.
35. Radebe M, Nair K, Chonco F, Bishop K, Wright JK, van der Stok M, Bassett IV, Mncube Z, Altfeld M, Walker BD. Ndung'u T: limited immunogenicity of HIV CD8 + T-cell epitopes in acute clade C virus infection. *J Infect Dis*. 2011;204:768–76.
36. Ndhlovu ZM, Kanya P, Mewalal N, Klooverpris HN, Nkosi T, Pretorius K, Laher F, Ogunshola F, Chopera D, Shekhar K, et al. Magnitude and kinetics of CD8 + T cell activation during Hyperacute HIV infection impact viral set point. *Immunity*. 2015;43:591–604.
37. Kiguoya MW, Mann JK, Chopera D, Gounder K, Lee GQ, Hunt PW, Martin JN, Ball TB, Kimani J, Brumme ZL et al. Subtype-specific differences in gag-protease-driven replication capacity are consistent with intersubtype differences in HIV-1 Disease Progression. *J Virol* 2017, 91.
38. Jin SW, Mwimanzani FM, Mann JK, Bwana MB, Lee GQ, Brumme CJ, Hunt PW, Martin JN, Bangsberg DR, Ndung'u T, et al. Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5. *PLoS Pathog*. 2020;16:e1008813.
39. Mann JK, Byakwaga H, Kuang XT, Le AQ, Brumme CJ, Mwimanzani P, Omarjee S, Martin E, Lee GQ, Baraki B, et al. Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. *Retrovirology*. 2013;10:100.
40. Umviligihozo G, Cobarrubias KD, Chandrarathna S, Jin SW, Reddy N, Byakwaga H, Muzoora C, Bwana MB, Lee GQ, Hunt PW et al. Differential Vpu-Mediated CD4 and tetherin downregulation functions among major HIV-1 Group M Subtypes. *J Virol* 2020, 94.
41. Naidoo VL, Mann JK, Noble C, Adland E, Carlson JM, Thomas J, Brumme CJ, Thobakgale-Tshabalala CF, Brumme ZL, Brockman MA et al. Mother-to-child HIV Transmission Bottleneck selects for Consensus Virus with Lower gag-protease-driven replication capacity. *J Virol* 2017, 91.
42. Dong KL, Moodley A, Kwon DS, Ghebremichael MS, Dong M, Ismail N, Ndhlovu ZM, Mabuka JM, Muema DM, Pretorius K, et al. Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study. *Lancet HIV*. 2018;5:e35–e44.
43. Ndung'u T, Dong KL, Kwon DS, Walker BD. A FRESH approach: combining basic science and social good. *Sci Immunol* 2018, 3.
44. Lee GQ, Reddy K, Einkauf KB, Gounder K, Chevalier JM, Dong KL, Walker BD, Yu XG, Ndung'u T, Lichtenfeld M. HIV-1 DNA sequence diversity and evolution during acute subtype C infection. *Nat Commun*. 2019;10:2737.
45. Muema DM, Akilimali NA, Ndumnego OC, Rasehlo SS, Durgiah R, Ojwach DBA, Ismail N, Dong M, Moodley A, Dong KL, et al. Association between the cytokine storm, immune cell dynamics, and viral replicative capacity in hyperacute HIV infection. *BMC Med*. 2020;18:81.
46. Naidoo KK, Ndumnego OC, Ismail N, Dong KL, Ndung'u T. Antigen presenting cells contribute to Persistent Immune Activation despite antiretroviral therapy initiation during Hyperacute HIV-1 infection. *Front Immunol*. 2021;12:738743.
47. Ndhlovu ZM, Kazer SW, Nkosi T, Ogunshola F, Muema DM, Anmole G, Swann SA, Moodley A, Dong K, Reddy T et al. Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection. *Sci Transl Med* 2019, 11.
48. Ndung'u T, McCune JM, Deeks SG. Why and where an HIV cure is needed and how it might be achieved. *Nature*. 2019;576:397–405.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.